Novo Nordisk Reports Earnings While Trading Like the Obesity Boom Already Ended

Novo Nordisk A/S (NVO) reports first-quarter 2026 earnings before market open on May 6, with the consensus estimate calling for $0.87 per share—down from $0.92 in the prior quarter and marking a 5.43% decline from the same quarter last year. The central question facing investors is whether the Danish pharmaceutical giant can stabilize its GLP-1 franchise amid intensifying competition from Eli Lilly, mounting pricing pressure in the United States, and a subdued 2026 outlook that has dampened enthusiasm for its newly launched oral Wegovy pill.

Part 1: Earnings Preview

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health through its portfolio of insulin therapies and GLP-1 receptor agonists, including blockbuster drugs Ozempic (for type 2 diabetes) and Wegovy (for obesity). The company also maintains a rare disease segment focused on hemophilia and growth disorders.

Novo Nordisk is scheduled to report first-quarter 2026 results before market open on Wednesday, May 6, with a conference call at 7:00 AM ET. Wall Street expects earnings of $0.87 per share on revenue of $11.12 billion. The company most recently reported fourth-quarter 2025 earnings of $1.00 per share, which beat the consensus estimate of $0.90 by $0.11. Year-over-year, the Q1 2026 estimate of $0.87 represents a 5.43% decline from the $0.92 reported in Q1 2025, reflecting the structural headwinds now weighing on the business.

Three key narrative themes define this earnings story:

GLP-1 Franchise Under Pressure: Novo Nordisk's core growth engine—semaglutide-based drugs Ozempic and Wegovy—faces mounting challenges from Eli Lilly's competing tirzepatide products (Mounjaro and Zepbound), which generated combined sales of $12.82 billion in Lilly's first quarter and now comprise roughly 65% of Lilly's total revenue. Lilly's recent earnings beat, raised guidance, and April launch of its oral GLP-1 pill Foundayo have widened the competitive gap. Investors will scrutinize whether Novo's own oral Wegovy pill, launched in early January and shipping in the U.S. starting May 4, can offset share losses and pricing pressure in the lucrative U.S. market.

Weak 2026 Outlook Signals Limited Momentum: Novo Nordisk's subdued 2026 guidance projects core sales and operating profit to decline 5–13% on a constant exchange rate basis, with even reported figures suggesting largely flat sales and only modest profit growth once a one-off $4.2 billion U.S. 340B rebate reversal is excluded. This weaker-than-expected trajectory has dampened investor confidence and suggests first-quarter sales growth for Wegovy and Ozempic likely remained under pressure, with higher R&D and commercial spending further straining margins.

Regulatory and Competitive Dynamics: The FDA's recent moves to restrict mass compounding of GLP-1 active ingredients should help protect branded pricing and volumes by making it harder for copycat alternatives to scale. However, Canada's approval of a second generic semaglutide (Apotex) signals increasing global generic competition that could undercut Novo's pricing and margins in core markets over time. Meanwhile, distribution wins—including WeightWatchers Med+ and GoodRx adding the oral Ozempic pill—should support uptake and patient access for the oral launch.

Leading analysts remain cautious heading into the release. Kepler Capital Markets downgraded Novo Nordisk from Buy to Hold in late February, while TD Cowen cut its rating from Buy to Hold with a $42 price target in early March, citing limited near-term momentum. JPMorgan Chase and BMO Capital Markets both maintain Neutral ratings, reflecting the view that competitive intensity and pricing headwinds will constrain growth in the near term. Wolfe Research initiated coverage with a Peer Perform rating in late March, noting that while Novo retains leadership in the GLP-1 space, the company's growth trajectory has suffered over the past year and the oral Wegovy pill is unlikely to meaningfully offset near-term challenges.

Part 2: Historical Earnings Performance

Novo Nordisk has delivered a strong track record of earnings beats over the past year, exceeding analyst estimates in three of the last four quarters and matching expectations in the remaining period. The company's average earnings surprise over the trailing four quarters stands at 11.97%, reflecting consistent operational execution even as the business faces structural headwinds.

The most recent quarter—Q4 2025—saw Novo report $1.00 per share, beating the $0.90 consensus by $0.11 or 11.11%. This followed an even stronger Q3 2025 performance, where the company posted $1.02 per share against a $0.77 estimate, delivering a 32.47% surprise. Q2 2025 also beat expectations, with $0.97 per share versus the $0.93 estimate (a 4.30% surprise), while Q1 2025 came in exactly at the $0.92 consensus.

The pattern reveals a company that has consistently outperformed lowered expectations, particularly in the back half of 2025 when competitive concerns intensified. However, the magnitude of beats has varied significantly—from the dramatic 32.47% upside in Q3 to the more modest 4.30% in Q2—suggesting that while Novo has managed to exceed estimates, the underlying business momentum has been uneven. With estimates for Q1 2026 revised down from $0.92 to $0.87 in recent months, investors will watch closely to see whether the company can continue its streak of positive surprises or whether the structural challenges finally catch up to results.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Novo Nordisk typically reports earnings before market open, meaning Day 0 represents the first trading session where the market reacts to results, while Day +1 captures follow-through momentum.

Novo Nordisk's post-earnings price action has been volatile and directionally mixed, with an average absolute Day 0 move of 4.11% and an average absolute Day +1 move of 4.47%. The stock has shown no consistent pattern—moving sharply in both directions depending on the quarter—but the magnitude of moves has been significant, often exceeding 4% on the day of the announcement.

The most dramatic reaction came after the August 2024 report, when the stock plunged 8.37% on Day 0 before rebounding 7.50% on Day +1, reflecting initial disappointment followed by bargain-hunting. More recently, the February 2026 report triggered a 6.18% decline on Day 0 and an 8.16% drop on Day +1, as investors reacted negatively to the company's weak 2026 outlook despite the earnings beat. Conversely, the February 2025 report saw the stock rally 3.76% on Day 0 and add another 1.68% on Day +1, demonstrating that positive surprises can drive sustained upside.

The average Day 0 intraday range of 3.94% and Day +1 range of 3.48% underscore the stock's tendency to swing widely in the immediate aftermath of results. Investors should prepare for significant volatility, with the direction heavily dependent on whether the company can deliver a meaningful positive surprise and provide reassuring commentary on its competitive positioning and 2026 outlook.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 6.14% (or $2.75) through the May 8 weekly expiration, which is notably higher than the stock's average historical Day 0 move of 4.11% but closer to the average Day +1 move of 4.47%. This suggests options traders are anticipating above-average volatility for this release, likely reflecting heightened uncertainty around the company's ability to stabilize its GLP-1 franchise and provide clarity on the oral Wegovy pill's early traction.

Part 3: What Analysts Are Saying

Analysts maintain a cautious stance on Novo Nordisk heading into earnings, with the consensus rating at 3.09 on the five-point scale—squarely in Hold territory. The average price target of $45.66 implies just 1.8% upside from the current price of $44.87, reflecting limited conviction in near-term appreciation potential.

The breakdown of 23 analyst ratings shows a defensive posture: 2 Strong Buys, 0 Moderate Buys, 20 Holds, 0 Moderate Sells, and 1 Strong Sell. The overwhelming concentration in the Hold category—representing 87% of all ratings—signals that most analysts are adopting a wait-and-see approach, unwilling to recommend aggressive accumulation given the competitive and pricing headwinds but also not ready to abandon the stock entirely given its long-term franchise value.

Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 3.09. This stability suggests analysts are in a holding pattern, awaiting clearer evidence that the company can stabilize its growth trajectory and demonstrate that the oral Wegovy pill can meaningfully offset share losses to Eli Lilly. The wide range of price targets—from a low of $36.00 to a high of $55.23—underscores the divergence of views, with bears seeing further downside risk and bulls betting on a recovery in the GLP-1 franchise over time.

Part 4: Technical Picture

Novo Nordisk's technical setup heading into earnings reflects a stock attempting to recover from a prolonged downtrend but still facing resistance from longer-term moving averages. The Barchart Technical Opinion currently registers a 40% Sell signal, an improvement from the 56% Sell reading one week ago and the 100% Sell signal one month ago, indicating that near-term momentum has stabilized even as the broader trend remains weak.

Timeframe Analysis:

• Short-term (Hold): Neutral reading suggests the stock has found near-term footing after recent weakness
• Medium-term (50% Sell): Moderate sell signal reflects ongoing consolidation and lack of conviction in the intermediate timeframe
• Long-term (100% Sell): Strong sell signal underscores persistent weakness in the longer-term trend, with the stock still well below its 100-day and 200-day moving averages

The trend is characterized as Soft in strength and Weakest in direction, indicating that while selling pressure has eased in recent sessions, the stock lacks the momentum to mount a sustained recovery and remains vulnerable to renewed downside if earnings disappoint.

The stock is trading at $44.87, above its 5-day ($43.13), 10-day ($41.69), 20-day ($40.44), and 50-day ($38.68) moving averages, confirming the recent bounce off the lows. However, it remains below the critical 100-day ($45.97) and 200-day ($49.87) moving averages, which now serve as overhead resistance. The 100-day average at $45.97 sits just above the current price and will be a key level to watch—a decisive break above it on strong earnings could signal a shift in momentum, while a rejection would reinforce the bearish longer-term trend.

Key technical levels to watch include the 100-day moving average at $45.97 as immediate resistance and the 50-day moving average at $38.68 as support. The stock's ability to hold above the shorter-term moving averages while challenging the 100-day will be critical in determining whether the recent stabilization can evolve into a sustained recovery. Overall, the technical setup is cautiously neutral heading into earnings—the stock has arrested its decline and is showing signs of near-term stabilization, but it remains in a longer-term downtrend and will need a strong earnings beat and reassuring guidance to break through overhead resistance and shift sentiment. Investors should be prepared for significant volatility, with the options market pricing a 6.14% move that could easily test either the $47.62 upside target or the $42.12 downside level depending on the results and management commentary.